PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it ...

PTC Inc. (NASDAQ:PTC) Q1 2026 Earnings Call Transcript February 4, 2026 PTC Inc. beats earnings expectations. Reported EPS is $119797.12, expectations were $1.59. Operator: Good evening, ladies and ...

Solid Q1 financials: Constant-currency ARR grew ~9% year-over-year excluding Kepware and ThingWorx (8.4% including them), free cash flow was $267 million (up 13% YoY), and management raised ...

PTC Inc. PTC is scheduled to report first-quarter fiscal 2026 results on Feb. 4, after market close. For the quarter, PTC anticipates revenues between $600 million and $660 million. Non-GAAP EPS is ...

DENVER (KDVR) — The Colorado Department of Revenue revealed on Wednesday how much eligible Coloradans can receive through its PTC Rebate Program and unveiled a new tax credit for Coloradans with ...

PTC specializes in computer-aided design, or CAD, and product lifecycle management, or PLM, to help manufacturing companies run their businesses more efficiently. We think cloud-based software ...

PTC Mathcad is the industry standard for engineering calculation software, providing a comprehensive platform for performing, documenting, and sharing technical calculations. Unlike spreadsheets or ...

PTC's annual run-rate growth supports super growth in cash flow for investors. The company's growth is even more impressive, considering the weak manufacturing environment over the last couple of ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...